Dalmia Group Starts Clinical Trial For Astha 15

Dalmia Group, committed to healthcare and an empowered, healthy India, goes back to its roots to formulate a magical drug that can cure COVID 19. Astha 15, a product of Ayurveda has been acknowledged by Ministry of Ayush and given the green signal to start clinical trials to evaluate its efficacy and safety.

Researchers and Ayurvedic doctors are confident that  Astha- 15, a polyherbal combination, will work as a treatment of COVID-19. The Dalmia Centre for Research and Development (DCRD), after years of extensive research, manufactured this polyherbal combination of 15 herbs that are also mentioned in the Indian System of Medicine. 

Dalmia Healthcare will begin its multi-center Phase III  trials within the set parameters. Its researchers will follow the set regulatory guidelines of Informed Consent The declaration, Insurance Terms, and EC approvals will be diligently followed.

"We are conducting Human trial of our highly efficient Ayurvedic composition which can potentially help in curing COVID 19 patients. Successful human trial of our medicine will not only curtail the impact of the contagious virus all across the world but will also establish the supremacy of Ayurveda, our the ancient system of medicine over any other methods of healthcare" said Mr. Sanjay Dalmia, Chairman, Dalmia